Changes for page Customer segments in Health and Wellbeing Living Labs
Last modified by Sarantis Dimitriadis on 2023/12/08 13:20
From version 5.4
edited by Sarantis Dimitriadis
on 2022/06/02 10:00
on 2022/06/02 10:00
Change comment:
There is no comment for this version
To version 6.1
edited by Sarantis Dimitriadis
on 2023/05/30 09:33
on 2023/05/30 09:33
Change comment:
There is no comment for this version
Summary
-
Page properties (1 modified, 0 added, 0 removed)
Details
- Page properties
-
- Content
-
... ... @@ -7,6 +7,8 @@ 7 7 (% class="western" lang="en-GB" style="text-align:justify" %) 8 8 (% lang="en-US" %)End users can be classified to non-professional and professional groups. Typical non-professional and professional end-user groups in health and wellbeing includes the following: 9 9 10 +: 11 + 10 10 * ((( 11 11 (% lang="en-US" %)**Non-professional end users:** 12 12 ... ... @@ -15,6 +15,8 @@ 15 15 * (% lang="en-US" %)**Public health and social service clients: **Those who use public services. 16 16 ))) 17 17 20 +: 21 + 18 18 * ((( 19 19 (% lang="en-US" %)**Professional end users** 20 20 ... ... @@ -25,9 +25,13 @@ 25 25 * (% lang="en-US" %)**Policy and decisions makers:** Those responsible for making policies and decisions at local, regional, national or international level. 26 26 ))) 27 27 32 +: 33 + 28 28 (% class="western" lang="en-GB" %) 29 29 (% lang="en-US" %)**Business-to-Business Customer (B2B):** B2B-customer is an organization that purchases living lab services from a living lab. B2B-customers can be classified to private, public, education/ research, civil society organizations and networks/cluster groups as follows: 30 30 37 +: 38 + 31 31 * ((( 32 32 (% lang="en-US" %)**Private sector organizations: **(business developers and researchers) 33 33 ... ... @@ -42,6 +42,8 @@ 42 42 * (% lang="en-US" %)Pharmaceutical companies 43 43 ))) 44 44 53 +: 54 + 45 45 * ((( 46 46 (% lang="en-GB" %) 47 47 (% lang="en-US" %)**Public sector organizations:** ... ... @@ -57,6 +57,8 @@ 57 57 * (% lang="en-US" %)**Public funder:** Government or other European, national, regional or local public institutions who is providing public funding for a specific living lab living lab research project via call for application process. 58 58 ))) 59 59 70 +: 71 + 60 60 * ((( 61 61 (% lang="en-GB" %) 62 62 (% lang="en-US" %)**Education and research organizations:** ... ... @@ -70,6 +70,8 @@ 70 70 * (% lang="en-US" %)**Private research organizations** such as technology and innovation centers 71 71 ))) 72 72 85 +: 86 + 73 73 * ((( 74 74 (% lang="en-GB" %) 75 75 (% lang="en-US" %)**Civil society organizations:** ... ... @@ -77,6 +77,8 @@ 77 77 * (% lang="en-US" %)Non-governmental organizations (NGO) and nonprofit entities operating at international, national, regional or local level. 78 78 ))) 79 79 94 +: 95 + 80 80 * ((( 81 81 (% lang="en-GB" %) 82 82 (% lang="en-US" %)**Networks and clusters:** ... ... @@ -85,276 +85,89 @@ 85 85 * (% lang="en-US" %)International, national, regional and local networks 86 86 ))) 87 87 88 -(% class="western" lang="en-GB" %) 89 -(% lang="en-US" %)Typical approaches to define (%%)non-professional end users (a.k.a. study participants) in health and wellbeing living lab projects are presented in Table . 104 +: 90 90 91 - 92 -(% cellspacing="0" class="table-striped" dir="ltr" style="margin-left:auto; margin-right:auto" %) 93 -|(% colspan="4" style="border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; height:5px; padding:0in 0.08in; width:628px" %)((( 94 -(% class="western" lang="en-GB" style="text-align:center" %) 95 -(% lang="en-US" style="font-family:Calibri,serif" %)**Age or age group** 96 -))) 97 -|(% style="border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:none; height:5px; padding:0in 0.08in; width:146px" %)((( 98 98 (% class="western" lang="en-GB" %) 99 -(% lang="en-US" style="font-family:Calibri,serif" %)Specific age range 100 -)))|(% style="border-bottom:1px solid #000000; border-left:none; border-right:1px solid #000000; border-top:none; padding-bottom:0in; padding-left:0in; padding-right:0.08in; padding-top:0in; width:146px" %)((( 101 -(% class="western" %) 107 +(% lang="en-US" %)Typical approaches to define (%%)non-professional end users (a.k.a. study participants) in health and wellbeing living lab projects are presented in the following table . 108 + 109 +(% style="height:1004px; margin-left:auto; margin-right:auto; width:1694px" %) 110 +|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:11px; text-align:center; vertical-align:middle; width:634px" %)**Age groups** 111 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)((( 112 +(% lang="en-US" %)Specific age range 113 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)((( 102 102 103 -)))|(% style="border- bottom:1px solid #000000; border-left:none; border-right:1px solid#000000; border-top:none; padding-bottom:0in;padding-left:0in;padding-right:0.08in;padding-top:0in; width:146px" %)(((115 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)((( 104 104 (% class="western" %) 105 105 106 -)))|(% style="border- bottom:1px solid #000000; border-left:none; border-right:1px solid#000000; border-top:none; padding-bottom:0in;padding-left:0in;padding-right:0.08in;padding-top:0in; width:147px" %)(((118 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)((( 107 107 (% class="western" %) 108 108 109 109 ))) 110 -|(% style="border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:none; height:6px; padding:0in 0.08in; width:146px" %)((( 111 -(% class="western" lang="en-GB" %) 112 -(% lang="en-US" style="font-family:Calibri,serif" %)Elderly 113 -)))|(% style="border-bottom:1px solid #000000; border-left:none; border-right:1px solid #000000; border-top:none; padding-bottom:0in; padding-left:0in; padding-right:0.08in; padding-top:0in; width:146px" %)((( 114 -(% class="western" lang="en-GB" %) 115 -(% lang="en-US" style="font-family:Calibri,serif" %)Adults 116 -)))|(% style="border-bottom:1px solid #000000; border-left:none; border-right:1px solid #000000; border-top:none; padding-bottom:0in; padding-left:0in; padding-right:0.08in; padding-top:0in; width:146px" %)((( 117 -(% class="western" lang="en-GB" %) 118 -(% lang="en-US" style="font-family:Calibri,serif" %)Youth 119 -)))|(% style="border-bottom:1px solid #000000; border-left:none; border-right:1px solid #000000; border-top:none; padding-bottom:0in; padding-left:0in; padding-right:0.08in; padding-top:0in; width:147px" %)((( 120 -(% class="western" lang="en-GB" %) 121 -(% lang="en-US" style="font-family:Calibri,serif" %)Children 122 -))) 123 -|(% style="border-bottom:none; border-left:none; border-right:none; border-top:none; height:6px; padding:0in; width:146px" %)((( 122 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)Adolescents|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:153px" %)Adults|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:153px" %)Older Adults|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:152px" %)General Population 123 +|(% colspan="4" style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; vertical-align:top; width:634px" %)((( 124 124 (% class="western" %) 125 125 126 -)))|(% style="border-bottom:none; border-left:none; border-right:none; border-top:none; padding:0in; width:146px" %)((( 127 -(% class="western" %) 128 - 129 -)))|(% style="border-bottom:none; border-left:none; border-right:none; border-top:none; padding:0in; width:146px" %)((( 130 -(% class="western" %) 131 - 132 -)))|(% style="border-bottom:none; border-left:none; border-right:none; border-top:none; padding:0in; width:147px" %)((( 133 -(% class="western" %) 134 - 135 135 ))) 136 -|(% colspan="4" style="border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; height:6px; padding:0in 0.08in; vertical-align:top; width:628px" %)((( 137 -(% class="western" lang="en-GB" style="text-align:center" %) 138 -(% lang="en-US" style="font-family:Calibri,serif" %)**Health status** 139 -))) 140 -|(% style="border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:none; height:6px; padding:0in 0.08in; width:146px" %)((( 127 +|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)**Adolescents Health status (disease, disorder or disability)** 128 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)((( 141 141 (% class="western" lang="en-GB" %) 142 -(% lang="en-US" style="font-family:Calibri,serif"%)Healthy143 -)))|(% style="border- bottom:1px solid #000000; border-left:none; border-right:1px solid#000000;border-top:none; padding-bottom:0in;padding-left:0in; padding-right:0.08in; padding-top:0in; width:146px" %)(((130 +(% lang="en-US" %)Healthy 131 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:153px" %)((( 144 144 (% class="western" lang="en-GB" %) 145 - (%lang="en-US" style="font-family:Calibri,serif" %)Patient146 -)))|(% style="border- bottom:1px solid #000000; border-left:none; border-right:1px solid#000000;border-top:none; padding-bottom:0in;padding-left:0in; padding-right:0.08in; padding-top:0in; width:146px" %)(((133 + 134 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:153px" %)((( 147 147 (% class="western" lang="en-GB" %) 148 - (%lang="en-US" style="font-family:Calibri,serif" %)Rehabilitant149 -)))|(% style="border- bottom:1px solid #000000; border-left:none; border-right:1px solid#000000;border-top:none; padding-bottom:0in;padding-left:0in; padding-right:0.08in; padding-top:0in; width:147px" %)(((136 + 137 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:152px" %)((( 150 150 (% class="western" lang="en-GB" %) 151 - (%lang="en-US" style="font-family:Calibri,serif" %)Recovered/Survivor139 + 152 152 ))) 153 -|(% style="border- bottom:none; border-left:none; border-right:none; border-top:none; height:6px;padding:0in; width:146px" %)(((141 +|(% colspan="4" style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; vertical-align:top; width:634px" %)((( 154 154 (% class="western" %) 155 155 156 -)))|(% style="border-bottom:none; border-left:none; border-right:none; border-top:none; padding:0in; width:146px" %)((( 144 +))) 145 +|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)**Adults Health status (disease, disorder or disability)** 146 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)Healthy|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)Schizophrenia|Multiple-Sclerosis|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)Parkinson Disease 147 +|Post-Stroke Patients with Moving or Linguistic Disability|Mild Cognitive Impairment|Sleep Disorders: e.g., Apnea, Hypopnea|With Disability 148 +|Healthy with Possible Chronic Conditions|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %) |(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %) |(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %) 149 +|(% colspan="4" style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; vertical-align:top; width:634px" %)((( 157 157 (% class="western" %) 158 158 159 -)))|(% style="border-bottom:none; border-left:none; border-right:none; border-top:none; padding:0in; width:146px" %)((( 160 -(% class="western" %) 161 - 162 -)))|(% style="border-bottom:none; border-left:none; border-right:none; border-top:none; padding:0in; width:147px" %)((( 163 -(% class="western" %) 164 - 165 165 ))) 166 -|(% colspan="4" style="border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; height:6px; padding:0in 0.08in; vertical-align:top; width:628px" %)((( 167 -(% class="western" lang="en-GB" style="text-align:center" %) 168 -(% lang="en-US" style="font-family:Calibri,serif" %)**A specific disease, disorder or disability** 169 -))) 170 -|(% style="border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:none; height:24px; padding:0in 0.08in; width:146px" %)((( 171 -(% class="western" lang="en-GB" %) 172 -(% lang="en-US" style="font-family:Calibri,serif" %)ADHD 173 -)))|(% style="border-bottom:1px solid #000000; border-left:none; border-right:1px solid #000000; border-top:none; padding-bottom:0in; padding-left:0in; padding-right:0.08in; padding-top:0in; width:146px" %)((( 174 -(% class="western" lang="en-GB" %) 175 -(% lang="en-US" style="font-family:Calibri,serif" %)Dementia 176 -)))|(% style="border-bottom:1px solid #000000; border-left:none; border-right:1px solid #000000; border-top:none; padding-bottom:0in; padding-left:0in; padding-right:0.08in; padding-top:0in; width:146px" %)((( 177 -(% class="western" lang="en-GB" %) 178 -(% lang="en-US" style="font-family:Calibri,serif" %)Parkinsons’ disease 179 -)))|(% style="border-bottom:1px solid #000000; border-left:none; border-right:1px solid #000000; border-top:none; padding-bottom:0in; padding-left:0in; padding-right:0.08in; padding-top:0in; width:147px" %)((( 180 -(% class="western" lang="en-GB" %) 181 -(% lang="en-US" style="font-family:Calibri,serif" %)Loneliness and Social Isolation 182 -))) 183 -|(% style="border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:none; height:5px; padding:0in 0.08in; width:146px" %)((( 184 -(% class="western" lang="en-GB" %) 185 -(% lang="en-US" style="font-family:Calibri,serif" %)Autism 186 -)))|(% style="border-bottom:1px solid #000000; border-left:none; border-right:1px solid #000000; border-top:none; padding-bottom:0in; padding-left:0in; padding-right:0.08in; padding-top:0in; width:146px" %)((( 187 -(% class="western" lang="en-GB" %) 188 -(% lang="en-US" style="font-family:Calibri,serif" %)Down syndrome 189 -)))|(% style="border-bottom:1px solid #000000; border-left:none; border-right:1px solid #000000; border-top:none; padding-bottom:0in; padding-left:0in; padding-right:0.08in; padding-top:0in; width:146px" %)((( 190 -(% class="western" lang="en-GB" %) 191 -(% lang="en-US" style="font-family:Calibri,serif" %)Physical disability 192 -)))|(% style="border-bottom:1px solid #000000; border-left:none; border-right:1px solid #000000; border-top:none; padding-bottom:0in; padding-left:0in; padding-right:0.08in; padding-top:0in; width:147px" %)((( 193 -(% class="western" lang="en-GB" %) 194 -(% lang="en-US" style="font-family:Calibri,serif" %)Mental health 195 -))) 196 -|(% style="border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:none; height:24px; padding:0in 0.08in; width:146px" %)((( 197 -(% class="western" lang="en-GB" %) 198 -(% lang="en-US" style="font-family:Calibri,serif" %)Cardiovascular disease 199 -)))|(% style="border-bottom:1px solid #000000; border-left:none; border-right:1px solid #000000; border-top:none; padding-bottom:0in; padding-left:0in; padding-right:0.08in; padding-top:0in; width:146px" %)((( 200 -(% class="western" lang="en-GB" %) 201 -(% lang="en-US" style="font-family:Calibri,serif" %)Idiopathic pulmonary fibrosis (IPF) 202 -)))|(% style="border-bottom:1px solid #000000; border-left:none; border-right:1px solid #000000; border-top:none; padding-bottom:0in; padding-left:0in; padding-right:0.08in; padding-top:0in; width:146px" %)((( 203 -(% class="western" lang="en-GB" %) 204 -(% lang="en-US" style="font-family:Calibri,serif" %)Sleep apnea/apnea 205 -)))|(% style="border-bottom:1px solid #000000; border-left:none; border-right:1px solid #000000; border-top:none; padding-bottom:0in; padding-left:0in; padding-right:0.08in; padding-top:0in; width:147px" %)((( 206 -(% class="western" lang="en-GB" %) 207 -(% lang="en-US" style="font-family:Calibri,serif" %)Mild cognitive impairment 208 -))) 209 -|(% style="border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:none; height:24px; padding:0in 0.08in; width:146px" %)((( 210 -(% class="western" lang="en-GB" %) 211 -(% lang="en-US" style="font-family:Calibri,serif" %)Chronic Obstructive Pulmonary Disease (COPD) 212 -)))|(% style="border-bottom:1px solid #000000; border-left:none; border-right:1px solid #000000; border-top:none; padding-bottom:0in; padding-left:0in; padding-right:0.08in; padding-top:0in; width:146px" %)((( 213 -(% class="western" lang="en-GB" %) 214 -(% lang="en-US" style="font-family:Calibri,serif" %)Language disability 215 -)))|(% style="border-bottom:1px solid #000000; border-left:none; border-right:1px solid #000000; border-top:none; padding-bottom:0in; padding-left:0in; padding-right:0.08in; padding-top:0in; width:146px" %)((( 216 -(% class="western" lang="en-GB" %) 217 -(% lang="en-US" style="font-family:Calibri,serif" %)Substance abuse (drugs, alcohol) 218 -)))|(% style="border-bottom:1px solid #000000; border-left:none; border-right:1px solid #000000; border-top:none; padding-bottom:0in; padding-left:0in; padding-right:0.08in; padding-top:0in; width:147px" %)((( 219 -(% class="western" lang="en-GB" %) 220 -(% lang="en-US" style="font-family:Calibri,serif" %)Multiple sclerosis 221 -))) 222 -|(% style="border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:none; height:44px; padding:0in 0.08in; width:146px" %)((( 223 -(% class="western" lang="en-GB" %) 224 -(% lang="en-US" style="font-family:Calibri,serif" %)Cognitive disorder (mild, major) 225 -)))|(% style="border-bottom:1px solid #000000; border-left:none; border-right:1px solid #000000; border-top:none; padding-bottom:0in; padding-left:0in; padding-right:0.08in; padding-top:0in; width:146px" %)((( 226 -(% class="western" lang="en-GB" %) 227 -(% lang="en-US" style="font-family:Calibri,serif" %)Intellectual disability/ Learning difficulty/ Mental retardation 228 -)))|(% style="border-bottom:1px solid #000000; border-left:none; border-right:1px solid #000000; border-top:none; padding-bottom:0in; padding-left:0in; padding-right:0.08in; padding-top:0in; width:146px" %)((( 229 -(% class="western" lang="en-GB" %) 230 -(% lang="en-US" style="font-family:Calibri,serif" %)Trauma patient 231 - 232 -(% class="western" lang="en-GB" %) 233 -(% lang="en-US" style="font-family:Calibri,serif" %)(e.g., a spinal cord injury) 234 -)))|(% style="border-bottom:1px solid #000000; border-left:none; border-right:1px solid #000000; border-top:none; padding-bottom:0in; padding-left:0in; padding-right:0.08in; padding-top:0in; width:147px" %)((( 235 -(% class="western" lang="en-GB" %) 236 -(% lang="en-US" style="font-family:Calibri,serif" %)Neurodegenerative diseases 237 -))) 238 -|(% style="border-bottom:none; border-left:none; border-right:none; border-top:none; height:6px; padding:0in; width:146px" %)((( 153 +|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)**Older Adults Health status (disease, disorder or disability)** 154 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)Healthy|Parkinson Disease|Mild Cognitive Impairment|With Disability|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)((( 239 239 (% class="western" %) 240 240 241 -)))|(% style="border-bottom:none; border-left:none; border-right:none; border-top:none; padding:0in; width:146px" %)((( 242 -(% class="western" %) 243 - 244 -)))|(% style="border-bottom:none; border-left:none; border-right:none; border-top:none; padding:0in; width:146px" %)((( 245 -(% class="western" %) 246 - 247 -)))|(% style="border-bottom:none; border-left:none; border-right:none; border-top:none; padding:0in; width:147px" %)((( 248 -(% class="western" %) 249 - 250 250 ))) 251 -|(% colspan="4" style="border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; height:6px; padding:0in 0.08in; vertical-align:top; width:628px" %)((( 252 -(% class="western" lang="en-GB" style="text-align:center" %) 253 -(% lang="en-US" style="font-family:Calibri,serif" %)**Clients of a specific service** 254 -))) 255 -|(% style="border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:none; height:5px; padding:0in 0.08in; width:146px" %)((( 158 +|Healthy with Possible Chronic Conditions|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)((( 256 256 (% class="western" lang="en-GB" %) 257 -(% lang="en-US" style="font-family:Calibri,serif" %)Child welfare 258 -)))|(% style="border-bottom:1px solid #000000; border-left:none; border-right:1px solid #000000; border-top:none; padding-bottom:0in; padding-left:0in; padding-right:0.08in; padding-top:0in; width:146px" %)((( 259 -(% class="western" lang="en-GB" %) 260 -(% lang="en-US" style="font-family:Calibri,serif" %)Nursing home 261 -)))|(% style="border-bottom:1px solid #000000; border-left:none; border-right:1px solid #000000; border-top:none; padding-bottom:0in; padding-left:0in; padding-right:0.08in; padding-top:0in; width:146px" %)((( 262 -(% class="western" lang="en-GB" %) 263 -(% lang="en-US" style="font-family:Calibri,serif" %)Employment service 264 -)))|(% style="border-bottom:1px solid #000000; border-left:none; border-right:1px solid #000000; border-top:none; padding-bottom:0in; padding-left:0in; padding-right:0.08in; padding-top:0in; width:147px" %)((( 265 -(% class="western" %) 266 266 267 -))) 268 -|(% style="border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:none; height:6px; padding:0in 0.08in; width:146px" %)((( 161 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)((( 269 269 (% class="western" lang="en-GB" %) 270 -(% lang="en-US" style="font-family:Calibri,serif" %)Early childhood education 271 -)))|(% style="border-bottom:1px solid #000000; border-left:none; border-right:1px solid #000000; border-top:none; padding-bottom:0in; padding-left:0in; padding-right:0.08in; padding-top:0in; width:146px" %)((( 272 -(% class="western" lang="en-GB" %) 273 -(% lang="en-US" style="font-family:Calibri,serif" %)Home care 274 -)))|(% style="border-bottom:1px solid #000000; border-left:none; border-right:1px solid #000000; border-top:none; padding-bottom:0in; padding-left:0in; padding-right:0.08in; padding-top:0in; width:146px" %)((( 275 -(% class="western" lang="en-GB" %) 276 276 277 -)))|(% style="border- bottom:1px solid #000000; border-left:none; border-right:1px solid#000000; border-top:none; padding-bottom:0in;padding-left:0in;padding-right:0.08in; padding-top:0in; width:147px" %)(((164 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)((( 278 278 (% class="western" lang="en-GB" %) 279 279 280 280 ))) 281 -|(% style="border- bottom:none; border-left:none; border-right:none; border-top:none; height:6px;padding:0in; width:146px" %)(((168 +|(% colspan="4" style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; vertical-align:top; width:634px" %)((( 282 282 (% class="western" %) 283 283 284 -)))|(% style="border-bottom:none; border-left:none; border-right:none; border-top:none; padding:0in; width:146px" %)((( 285 -(% class="western" %) 286 - 287 -)))|(% style="border-bottom:none; border-left:none; border-right:none; border-top:none; padding:0in; width:146px" %)((( 288 -(% class="western" %) 289 - 290 -)))|(% style="border-bottom:none; border-left:none; border-right:none; border-top:none; padding:0in; width:147px" %)((( 291 -(% class="western" %) 292 - 293 293 ))) 294 -|(% colspan="4" style="border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; height:6px; padding:0in 0.08in; vertical-align:top; width:628px" %)((( 295 -(% class="western" lang="en-GB" style="text-align:center" %) 296 -(% lang="en-US" style="font-family:Calibri,serif" %)**Vulnerable groups** 297 -))) 298 -|(% style="border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:none; height:44px; padding:0in 0.08in; width:146px" %)((( 172 +|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)**General Population Health status (disease, disorder or disability)** 173 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)Healthy|Ipf Patients|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)Prostate Cancer|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)((( 299 299 (% class="western" lang="en-GB" %) 300 -(% lang="en-US" style="font-family:Calibri,serif" %)Minors/Children 301 -)))|(% style="border-bottom:1px solid #000000; border-left:none; border-right:1px solid #000000; border-top:none; padding-bottom:0in; padding-left:0in; padding-right:0.08in; padding-top:0in; width:146px" %)((( 302 -(% class="western" lang="en-GB" %) 303 -(% lang="en-US" style="font-family:Calibri,serif" %)Single parents with minor children 304 -)))|(% style="border-bottom:1px solid #000000; border-left:none; border-right:1px solid #000000; border-top:none; padding-bottom:0in; padding-left:0in; padding-right:0.08in; padding-top:0in; width:146px" %)((( 305 -(% class="western" lang="en-GB" %) 306 -(% lang="en-US" style="font-family:Calibri,serif" %)Persons subjected to psychological, physical or sexual violence 307 -)))|(% style="border-bottom:1px solid #000000; border-left:none; border-right:1px solid #000000; border-top:none; padding-bottom:0in; padding-left:0in; padding-right:0.08in; padding-top:0in; width:147px" %)((( 308 -(% class="western" lang="en-GB" %) 309 -(% lang="en-US" style="font-family:Calibri,serif" %)Substance users 310 - 311 -(% class="western" lang="en-GB" %) 312 -(% lang="en-US" style="font-family:Calibri,serif" %)(drugs, alcohol) 175 +Down Syndrome 313 313 ))) 314 -|(% style="border-bot tom:1pxsolid#000000; border-left:1pxsolid#000000; border-right:1px solid#000000; border-top:none;height:24px;padding:0in0.08in; width:146px" %)(((177 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)Chronical Diseases: e.g., Persons With Chronic Pulmonary (Copd)|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)Cardiological Or Other Conditions (Aphasia)|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)Breast Cancer Survivors|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)((( 315 315 (% class="western" lang="en-GB" %) 316 -(% lang="en-US" style="font-family:Calibri,serif" %)Disabled people 317 -)))|(% style="border-bottom:1px solid #000000; border-left:none; border-right:1px solid #000000; border-top:none; padding-bottom:0in; padding-left:0in; padding-right:0.08in; padding-top:0in; width:146px" %)((( 318 -(% class="western" lang="en-GB" %) 319 -(% lang="en-US" style="font-family:Calibri,serif" %)Victims of trafficking in human beings 320 -)))|(% style="border-bottom:1px solid #000000; border-left:none; border-right:1px solid #000000; border-top:none; padding-bottom:0in; padding-left:0in; padding-right:0.08in; padding-top:0in; width:146px" %)((( 321 -(% class="western" lang="en-GB" %) 322 -(% lang="en-US" style="font-family:Calibri,serif" %)Ethnic minorities and immigrants 323 -)))|(% style="border-bottom:1px solid #000000; border-left:none; border-right:1px solid #000000; border-top:none; padding-bottom:0in; padding-left:0in; padding-right:0.08in; padding-top:0in; width:147px" %)((( 324 -(% class="western" lang="en-GB" %) 325 -(% lang="en-US" style="font-family:Calibri,serif" %)Isolated people 326 -))) 327 -|(% style="border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:none; height:24px; padding:0in 0.08in; width:146px" %)((( 328 -(% class="western" lang="en-GB" %) 329 -(% lang="en-US" style="font-family:Calibri,serif" %)Elderly people 330 -)))|(% style="border-bottom:1px solid #000000; border-left:none; border-right:1px solid #000000; border-top:none; padding-bottom:0in; padding-left:0in; padding-right:0.08in; padding-top:0in; width:146px" %)((( 331 -(% class="western" lang="en-GB" %) 332 -(% lang="en-US" style="font-family:Calibri,serif" %)Persons with serious illnesses 333 -)))|(% style="border-bottom:1px solid #000000; border-left:none; border-right:1px solid #000000; border-top:none; padding-bottom:0in; padding-left:0in; padding-right:0.08in; padding-top:0in; width:146px" %)((( 334 -(% class="western" lang="en-GB" %) 335 -(% lang="en-US" style="font-family:Calibri,serif" %)Homeless people 336 -)))|(% style="border-bottom:1px solid #000000; border-left:none; border-right:1px solid #000000; border-top:none; padding-bottom:0in; padding-left:0in; padding-right:0.08in; padding-top:0in; width:147px" %)((( 337 -(% class="western" lang="en-GB" %) 338 -(% lang="en-US" style="font-family:Calibri,serif" %)Ex-prisoners and people with criminal background 339 -))) 340 -|(% style="border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:none; height:5px; padding:0in 0.08in; width:146px" %)((( 341 -(% class="western" lang="en-GB" %) 342 -(% lang="en-US" style="font-family:Calibri,serif" %)Pregnant women 343 -)))|(% style="border-bottom:1px solid #000000; border-left:none; border-right:1px solid #000000; border-top:none; padding-bottom:0in; padding-left:0in; padding-right:0.08in; padding-top:0in; width:146px" %)((( 344 -(% class="western" lang="en-GB" %) 345 -(% lang="en-US" style="font-family:Calibri,serif" %)Persons with mental disorders 346 -)))|(% style="border-bottom:1px solid #000000; border-left:none; border-right:1px solid #000000; border-top:none; padding-bottom:0in; padding-left:0in; padding-right:0.08in; padding-top:0in; width:146px" %)((( 347 -(% class="western" lang="en-GB" %) 348 348 349 -)))|(% style="border-bottom:1px solid #000000; border-left:none; border-right:1px solid #000000; border-top:none; padding-bottom:0in; padding-left:0in; padding-right:0.08in; padding-top:0in; width:147px" %)((( 350 -(% class="western" lang="en-GB" %) 351 - 352 352 ))) 353 353 182 +: 183 + 354 354 (% class="western" lang="en-GB" %) 355 -(% lang="en-US" style="page-break-before:always" %)Living lab research infrastructure end users and B2B-customers (% style="page-break-before:always" %)in health and wellbeing living lab projects are presented in Table .185 +(% lang="en-US" style="page-break-before:always" %)Living lab research infrastructure end users and B2B-customers (% style="page-break-before:always" %)in health and wellbeing living lab projects are presented in (%%)the table below(% style="page-break-before:always" %) . 356 356 357 - 358 358 |**Researcher expertise**|**Brief use case description** 359 359 |Policy Makers|Studying the impact of new service models or new collaboration models in healthcare, designing or improving policies, gathering requirements for improving health and wellbeing of citizens, co-creation of research methodologies for policy making 360 360 |Experts in communication studies|Defining written, oral, visual and digital communication within a certain workplace. Evaluating (multi professional) healthcare team collaboration, communication and debriefing in various healthcare situations in simulated environments (especially in Simulation lab)